Aristotle University Of Thessaloniki (AUTH)
Επίπεδα νευροπεπτιδίου Υ και μελανοκορτίνης σε υπερτασικούς ασθενείς: ο ρόλος της παχυσαρκίας
Abstract
dc:descriptionObesity is a multifactorial chronic disease, developing through gene and environmental interaction, predisposes many serious pathological situations related to cardiovascular disease, like Arterial Hypertension (AH) and Diabetes Mellitus (DM), increases morbidity and mortality and constitutes a major threat to the public health in the present time. AH is a primary risk factor for the development of cardiovascular disease, is increased in obesity and their co-existence increases cardiovascular risk. Obesity induced AH is characterized by increased fluid volume, (Na and water retention), cardiac output and peripheral vascular resistance and often shows poor compliance to the current drug therapy. Many mechanisms are currently investigated to explain the obesity induced AH, the most important being the increased Sympathetic Nervous System (SNS) activity. In these mechanisms, many factors and mainly hormones produced by the fat tissue, like leptin, interact with each-other and with neuropeptides that are secreted in Central Nervous System (CNS)- mainly hypothalamus, and control the energy balance of human organism. The most important neuropeptides are the orexigenic Neuropeptide Y (NPY) and the anorexigenic a-Melanocyte Stimulating Hormone (a-MSH), which apart from controlling food intake, are currently considered to be involved in the increased SNS activity and obesity induced AH. In our study plasma levels of NPY and a-MSH were calculated in patients with AH and obesity, in order to clarify their role in obesity induced AH. 160 non diabetic patients and control groups from Hypertension Clinics of 1st Propedeutic Medical Department of Aristotles University of Thessaloniki, in AXEPA Hospital, with mild and moderate AH of recent onset, without on any drug therapy, were divided into 6 groups according to their Body Mass Index (BMI) in Normal Weight BMI<25 Kgr/cm² (NW), Overweight: 25≤BMI<30 Kgr/cm² (OW) and Obese: BMI≥30 Kgr/cm² (OB), and according to the existence or not of AH, in Hypertensives (H⁺) and normotensives (Hˉ), following the instructions of ESH/ESC 2007. Exclusion criteria were the existence of coronary disease, heart failure, renal disease, secondary AH, DM, endocrine gland diseases, stroke, pregnancy, alcohol consumption, retinopathy, depression, taking drugs that impair glucose metabolism, lipid lowering and for cardiovascular disease, situations that them or the drugs needed, influence neuropeptide plasma levels. The six groups in the study were: Group 1: NW/H⁺, 26 persons, (13 men, 13 women), Group 2: OW/H⁺, 28 persons, (14 men, 14 women), Group 3: OB/H⁺, 28 persons, (14 men, 14 women), Group 4: NW/Hˉ, 22 persons, (11 men, 11 women), Group 5: OW/Hˉ, 28 persons, (14 men, 14 women), Group 6: OB/Hˉ, 28 persons, (14 men, 14 women). In all patients plasma levels of NPY and a-MSH (with ΕLISA method-Enzyme-Linked Immunosorbent Assay), and plasma parameters Glu, Ure, Cre, UA, Chol, TRG, HDL, LDL, CRP, were calculated and echocardiogram was performed. After the statistical analysis with SPSS.15 the results are summarized as follow: Plasma NPY levels are statistically significantly increased in overweight and particularly in obese hypertensive patients compared to normal weight hypertensives and all the normotensives, in the total and in men separately (p<0.001). In female patients plasma NPY levels are statistically significantly increased in obese hypertensives compared to normal weight hypertensives and all normotensives (p<0.001), while small differentiation appears in overweight hypertensives in which NPY levels are increased compared to normal weight hypertensives and all the normotensives and decreased compared to obese hypertensives, but the differences are not statistically significant (P>0.05). NPY plasma levels are statistically significantly increased in hypertensive patients with central obesity compared to those with peripheral (p<0.001). On the contrary in normotensive patients NPY plasma levels are not related to central obesity (p>0.05). The same results go for the sexes separately. NPY plasma levels have no difference when men and women between them are compared (p>0.05). a-MSH plasma levels have no difference when comparing the six groups in our study, in the total and in men and women separately and have also no correlation with central obesity in the total, in men and in women hypertensives and normotensive patients.(p>0.05). On the contrary a-MSH plasma levels are statistically significant increased in all women compared to all men without this having to do with obesity or hypertension (p<0.05), while almost significantly increased are in hypertensive women with central obesity compared to hypertensive men with central obesity (p=0.06). Heart rate which shows increases SNS activity is statistically significant increased in overweight and obese hypertensives compared to normal weight hypertensives and normotensives (p<0.001) and increased but not statistically significant in overweight and obese normotensives (p>0.05). Plasma NPY levels are not related with heart echo findings in hypertensive patients in the total and in men and women separately (p>0.05). Plasma a-MSH levels are not related to heart echo findings in hypertensive patients in the total and in men separately (p>0.05). Statistically significant is the relation of increased plasma a-MSH levels with dilated dysfunction in normal weight hypertensives (p<0.05) and hypertensive women with central obesity (in the edge of significance, ANOVA p=0.03, Tukey index p=0.08). NPY and a-MSH plasma levels are not related in hypertensive patients of our study with any of the metabolic biochemical parameters (Glu, Chol, TRG, HDL, LDL) renal function parameters (Ure, Cre, UA) and inflammatory markers (CRP) (p>0.05). The results in this study show that NPY plasma levels are related to obesity induced hypertension, with parallel increase of heart rate, presumably due to SNS activity increase and especially with AH in central obesity. On the contrary, they don’t seem to be related with heart echo findings in recently diagnosed hypertensive patients. a-MSH plasma levels are not related with obesity induced hypertension , but are related to dilated dysfunction in hypertensive women with central obesity and hypertensive normal weight patients, something that could mean special tissue activity, but needs further investigation. Our results could become clinically interesting, since NPY increase could be used in AH treatment and NPY become target for treatment in hypertensives with increased body weight, whose AH is very difficult to treat since they often show resistance in current drug therapy. The connection of increased NPY plasma levels with SNS activity as a mechanism leading partly in obesity hypertension emphasizes the clinical significance of one specialized future drug therapy against NPY. About a-MSH clinically important could become our finding that connects it to dilated dysfunction of the heart, which needs as already mentioned, further investigation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Baltatzi, Maria
- Μπαλτατζή, Μαρία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19633